Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

To Prevent Shortages, US FDA Wants Sponsor To Provide Notifications Of Demand Spike

Executive Summary

Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.

You may also be interested in...



Demand Spike Sees Sandoz, Teva Fall Short On US Amoxicillin Supply

Infants and young children across the US are continuing to struggle to get access to one of the most common and recognized antibiotics, liquid-dose amoxicillin, amid a surge in demand for the drug that has hindered generics manufacturers.

Global Supply Chain Scrutiny And Investment In Domestic Alternatives For US Drug Shortages

Pharmaceutical supply chains may grow less efficient and less risk prone as US government gets more involved to ensure availability of pandemic and essential medicines. But what about pediatric oncology medicines and other treatments that save lives even though they may not be considered essential?

Sandoz Weighs In On US Adderall Shortages Amid Supply Disruption

A spike in demand for Adderall and its generic versions has left patients scrambling to have their prescriptions filled, making headline news in the US. Leading generics manufacturer Sandoz told Generics Bulletin its current experience amid the supply squeeze.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel